Premium
P1–342: Effects of solanezumab versus placebo administration on biomarkers in people with mild‐to‐moderate Alzheimer's disease: Results from two phase III clinical trials
Author(s) -
Dean Robert,
Siemers Eric,
Carlson Christopher,
Estergard Wahiba,
Sundell Karen,
Henley David,
Hake Ann,
Eads Jennifer,
Sexton Cora,
LiuSeifert Hong,
Sethuraman Gopalan,
Chen YunFei,
Gonzales Celedon,
Lachno D. Richard,
Gelfanova Valentina,
Talbot Jayne,
Racke Margaret,
Mintun Mark,
Pontecorvo Michael,
Willis Brian,
DeMattos Ronald,
Mohs Richard
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.568
Subject(s) - placebo , medicine , cerebrospinal fluid , gastroenterology , clinical trial , clinical endpoint , oncology , pathology , alternative medicine
ratiowas 4:1, consistent with the ratio in the general population; that for avagacestat was 1:1.75. NMSC incidence rates among avagacestat-treated patients were higher than those from the claims database. Conclusions: This is the first clinical report characterizing NMSC in patients treated with a GSI. The NMSCs observed were readily identified and easily managed without recurrence. Increased NMSC incidence (especially SCC) and inversion of BCC:SCC ratio suggest that Notch inhibition oncogenically effects SCC. Further evaluation is warranted to understand potential oncogenic or suppressor effects of similar agents on skin cancer subtypes. The algorithms utilized in this study may help accurately identify and manage skin malignancies in studies using agents that affect epidermal differentiation.